Biologics for pediatric moderate‐to‐severe plaque psoriasis: a systematic review and network meta‐analysis

Huang, I‐Hsin; Yu, Chia‐Ling; Tai, Cheng‐Chen; Tu, Yu‐Kang; Chi, Ching‐Chi

doi:10.1111/ddg.14832

Cited by 8 publications

(10 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The prevalence of migraine in the pediatric population is estimated 9.1%, rising after puberty. On the other hand, the mean onset age of psoriasis is about 15–30 years and the second peak of onset is 55–60 years while the prevalence of pediatric psoriasis ranges from 0.13% to 2.1% 33 . Both women and men share equal prevalence of psoriasis.…”

Section: Discussionmentioning

confidence: 99%

Bidirectional associations between psoriasis and migraine: A systematic review and meta‐analysis

Huang

Hung

Chi

2023

J Deutsche Derma Gesell

Self Cite

View full text Add to dashboard Cite

Background and Objectives:To evaluate the association between psoriasis and migraine. Patients and Methods: MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched for relevant observational studies from their respective inception to May 1, 2022. A random-effects model meta-analysis was performed to calculate the risk estimates quantifying the associations between psoriasis and migraine. We also performed a sensitivity analysis by including only studies with adjusted risk estimates and a subgroup analysis according to the severity of psoriasis. Results: We included 9 studies with 6,742,075 participants. The meta-analysis illustrated increased odds for prevalent migraine among patients with psoriasis (pooled OR: 1.69, 95% CI: 1.26-2.28) and increased odds for prevalent psoriasis among those with migraine (OR: 1.88, 95% CI: 1.32-3.67). A subgroup analysis of cohort studies demonstrated an increasingly higher risk of incident migraine in patients with mild psoriasis and severe psoriasis (IRR being 1.37 (95% CI 1.30-1.44) and 1.55 (95% CI 1.29-1.86), respectively). Conclusions: This meta-analysis revealed significant bidirectional associations between migraine and psoriasis. Greater severity of psoriasis appears to be associated with a higher risk of developing migraine. Clinicians should evaluate symptoms of migraine in patients with psoriasis and provide proper treatments.

show abstract

Section: Discussionmentioning

confidence: 99%

Bidirectional associations between psoriasis and migraine: A systematic review and meta‐analysis

Huang

Hung

Chi

2023

J Deutsche Derma Gesell

Self Cite

View full text Add to dashboard Cite

show abstract

“…2 Seither erschienen in dieser Zeitschrift Publikationen zur Psoriasis in dreistelliger Zahl. In jüngster Zeit umspannen die Themen grundlegende pathophysiologische Aspekte, [3][4][5] therapeutische Ansätze, [6][7][8][9][10][11] epidemiologische Fragen, 12 diagnostische und klinische Entwicklungen, [13][14][15] psychosoziale Aspekte, [16][17][18] bis hin zu Versorgungsforschung und Registerstudien. [19][20][21][22] Empfehlungen zur praktischen Umsetzung neuer Erkenntnisse kulminieren schließlich in Leitlinien.…”

Section: Wo Stehen Wir?unclassified

Aktuelle Entwicklungen und Perspektiven bei Psoriasis

Schön

Wilsmann‐Theis

2023

J Deutsche Derma Gesell

View full text Add to dashboard Cite

ZusammenfassungDie Erforschung kaum einer anderen Erkrankung hat so grundlegend neue Erkenntnisse über immunologischen Regulationen und gleichzeitig eine derart rasante Entwicklung innovativer Therapien hervorgebracht wie das Studium der Psoriasis. In dieser kurzen Übersichtsarbeit umreißen wir die Grundzüge der aktuellen Psoriasisforschung unter besonderer Berücksichtigung pathophysiologischer Vorgänge und der Meilensteine bei der Zulassung verschiedener Biologika und niedermolekularer Pharmaka. Nicht zuletzt durch die Psoriasisforschung verstehen wir das Zusammenspiel der Komponenten des angeborenen und des adaptiven Immunsystems immer besser. Neue Therapeutika greifen dabei an entscheidenden Punkten in regulatorische Netzwerke ein. Ausgehend vom derzeitigen Kenntnisstand skizzieren wir einige aus unserer Sicht wesentliche zukünftige Forschungsrichtungen sowie therapeutische und klinische Entwicklungen im Bereich der Psoriasis. Diese reichen von der Erforschung genetischer, epigenetischer, zellulärer und immunologischer Mechanismen über die Untersuchung spezifischer klinischer Formen der Psoriasis und individueller systemischer Auswirkungen der Krankheit sowie ihrer Behandlung bis hin zur Einbeziehung von Big Data und künstlicher Intelligenz. Ziele sind ein ganzheitliches Verständnis der Psoriasis von der molekularen bis zur organismischen und gesellschaftlichen Ebene und darauf aufbauend individualisierte Präventions‐ und Behandlungsstrategien. Trotz beeindruckender Fortschritte muss die Psoriasisforschung sowohl im kleinen als auch im großen Maßstab weiterentwickelt werden, um den Bedürfnissen von Behandlern und Patienten noch besser gerecht zu werden.

show abstract

“…The results of presented clinical trials are similar to those conducted in adult patients. 44 Meta-analysis using SUCRA (surface under cumulative ranking curve) performed by Huang et al 48 showed that among all available clinical trials with biologics in pediatric population (etanercept, adalimumab, ustekinumab, ixekizumab and secukinumab), low dose secukinumab showed the best PASI 90 response (84.7%), followed by ixekizumab (70.8%) at weeks 12–16. Similar analysis was provided by Gohlen at al.…”

Section: Psoriasis and Pediatric Psoriasis - Introductionmentioning

confidence: 99%

“…Meta analysis with such a small number of studies may be underpowered, therefore more published clinical and real-world studies, which are ongoing, would be beneficial for further assessment of secukinumab position in psoriasis treatment in children. 48 , 50 …”

Section: Psoriasis and Pediatric Psoriasis - Introductionmentioning

confidence: 99%

Secukinumab for the Treatment of Psoriasis in Pediatrics: Patient Selection and Acceptability

Niedźwiedź¹,

Lesiak²,

Ceryn³

et al. 2023

PPA

View full text Add to dashboard Cite

Psoriasis (PsO) is a chronic, systemic, immune-mediated inflammatory skin disease affecting 1% to 5% population worldwide. In one-third of patients, the first symptoms of PsO manifest in childhood, with a mean age of nine years. Psoriasis in children under 16 years of age constitutes 4% of dermatological problems in this age group. Chronic inflammation of the skin observed in PsO is associated with a development of potentially serious comorbidities, including psoriatic arthritis, hypertension, metabolic syndrome, cardiovascular diseases, inflammatory bowel disease, depression and anxiety. It is reported that among children with psoriasis between 5 and 16 years of age health-related quality of life is reduced by 30.5%. Early diagnosis and effective treatment are crucial in pediatric psoriatic patients to avoid future complications and stigmatization. Treatment for psoriasis consists of a range of topical medications, phototherapy and non-biologic and biologic systemic therapies. Approved biologics for PsO in pediatric patients include etanercept, adalimumab, ustekinumab, ixekizumab and secukinumab. Secukinumab, a recombinant, fully human monoclonal antibody targeting IL-17A, was approved by the EMA (2020) and FDA (2021) in pediatric patients above 6 years of age for the treatment of moderate to severe plaque psoriasis who are candidates for systemic therapy. This review discusses the selection and acceptability of secukinumab in children with psoriasis.

show abstract

Biologics for pediatric moderate‐to‐severe plaque psoriasis: a systematic review and network meta‐analysis

Cited by 8 publications

References 32 publications

Bidirectional associations between psoriasis and migraine: A systematic review and meta‐analysis

Bidirectional associations between psoriasis and migraine: A systematic review and meta‐analysis

Aktuelle Entwicklungen und Perspektiven bei Psoriasis

Secukinumab for the Treatment of Psoriasis in Pediatrics: Patient Selection and Acceptability

Contact Info

Product

Resources

About